Jasovich A - Search Results

Year	Number of Results
1983	1
1985	1
1990	1
1992	2
1998	1
1999	1
2000	1
2001	2
2002	4
2003	1
2006	1
2008	5
2009	3
2010	1
2011	2
2017	1
2024	0

1

Review of pharmacokinetic, pharmacodynamic and clinical studies with a modern combination of amoxicillin/sulbactam.

Soutric J, Bantar C, Caruso N, Heguilén R, Casellas JM Jr, Casellas JM, Farinati A, Jasovich A, Arenoso H, Rodriguez M. Soutric J, et al. Among authors: jasovich a. Chemotherapy. 2006;52(4):200-4. doi: 10.1159/000093593. Epub 2006 May 24. Chemotherapy. 2006. PMID: 16720984 Review.

2

A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients.

Rello J, Krenn CG, Locker G, Pilger E, Madl C, Balica L, Dugernier T, Laterre PF, Spapen H, Depuydt P, Vincent JL, Bogár L, Szabó Z, Völgyes B, Máñez R, Cakar N, Ramazanoglu A, Topeli A, Mastruzzo MA, Jasovich A, Remolif CG, Del Carmen Soria L, Andresen Hernandez MA, Ruiz Balart C, Krémer I, Molnár Z, von Sonnenburg F, Lyons A, Joannidis M, Burgmann H, Welte T, Klingler A, Hochreiter R, Westritschnig K. Rello J, et al. Among authors: jasovich a. Crit Care. 2017 Feb 4;21(1):22. doi: 10.1186/s13054-017-1601-9. Crit Care. 2017. PMID: 28159015 Free PMC article. Clinical Trial.

3

A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections.

Bantar C, Nicola F, Fernandez Canigia L, Arenoso HJ, Soutric J, Montoto M, Blanco M, Smayevsky J, Jasovich A. Bantar C, et al. Among authors: jasovich a. J Chemother. 2000 Jun;12(3):223-7. doi: 10.1179/joc.2000.12.3.223. J Chemother. 2000. PMID: 10877517

4

Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia: a clinical trial based on a pharmacodynamic model.

Jasovich A, Soutric J, Morera G, Mastruzzo M, Vesco E, Izaguirre M, Mobilia L, Prieto S, Franco D, Curcio D, Absi R, Larrateguy L, Bustos JL, Oliva ME, Arenoso H, Bantar C. Jasovich A, et al. J Chemother. 2002 Dec;14(6):591-6. doi: 10.1179/joc.2002.14.6.591. J Chemother. 2002. PMID: 12583551 Clinical Trial.

5

A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults.

Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, Imbeault D, Woods GL, Gesser RM; Protocol 021 Study Group. Jimenez-Cruz F, et al. Among authors: jasovich a. Urology. 2002 Jul;60(1):16-22. doi: 10.1016/s0090-4295(02)01664-3. Urology. 2002. PMID: 12100914 Clinical Trial.

6

Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.

Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S; CAPTIVATE Trial Group. Wunderink RG, et al. Am J Respir Crit Care Med. 2011 Jun 1;183(11):1561-8. doi: 10.1164/rccm.201007-1167OC. Epub 2011 Feb 4. Am J Respir Crit Care Med. 2011. PMID: 21297074 Clinical Trial.

7

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

Low DE, File TM Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 2 investigators. Low DE, et al. J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii33-44. doi: 10.1093/jac/dkr097. J Antimicrob Chemother. 2011. PMID: 21482568 Clinical Trial.

8

Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination, against Escherichia coli.

Bantar C, Nicola F, Arenoso HJ, Galas M, Soria L, Dana D, Rossi A, Bianchini H, Jasovich A. Bantar C, et al. Among authors: jasovich a. Antimicrob Agents Chemother. 1999 Jun;43(6):1503-4. doi: 10.1128/AAC.43.6.1503. Antimicrob Agents Chemother. 1999. PMID: 10348782 Free PMC article.

9

A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections.

Nicodemo AC, Robledo JA, Jasovich A, Neto W. Nicodemo AC, et al. Among authors: jasovich a. Int J Clin Pract. 1998 Mar;52(2):69-74. Int J Clin Pract. 1998. PMID: 9624783 Clinical Trial.

10

Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.

Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC; MOTIV (MOxifloxacin Treatment IV) Study Group. Torres A, et al. Clin Infect Dis. 2008 May 15;46(10):1499-509. doi: 10.1086/587519. Clin Infect Dis. 2008. PMID: 18419482 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

27 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year